TNF-a has been implicated in the pathogenesis of, and the immune response against, HIV-1 infection.
Introduction
Cytokines mediate important immunoregulatory functions, and changes in their relative levels play key roles in the immune response against human immunodeficiency virus type-1 (HIV-1) infection and the progression of HIV-1 infection to clinical AIDS (Fauci, 1996; Matsuyama et al., 1991) . Increased levels of proinflammatory cytokines, especially tumor necrosis factor alpha (TNF-a) and interleukin-6 (IL-6), were detected in plasma and tissue of patient with AIDS (Fauci, 1993; Navikas et al., 1995) . TNF-a has been strongly implicated in the progression of HIV-1 infection (Aukrust et al., 1994) . A possible mechanism for the progression of HIV-1 infection is that TNF-a enhances HIV-1 replication (Folks et al., 1989; Poli et al., 1990) . Another possibility is that TNF-a induces apoptosis of lymphocytes (Zheng et al., 1995) , which destroys T cells in the peripheral lymphoid systems (Badley et al., 1997; Herbein et al., 1998) .
On the other hand, TNF-a is also involved in controlling the immune responses in some viral infections (Herbein and O'Brien, 2000) . Pretreatment of TNF-a inhibited replication of the monocyte-tropic strain of HIV-1 (Herbein and Gordon, 1997) . Thus, as a pleiotropic cytokine, TNF-a might contribute not only to the pathogenesis of HIV-1 infection but also to the immune response against HIV-1 infection. Despite the importance of TNF-a, little information is available on its role in the pathogenesis of HIV-1 infection in vivo. The early events of infection are especially unclear because it is difficult to monitor humans immediately after they are infected.
Chimeric simian and human immunodeficiency virus (SHIV) clones containing the HIV-1 tat, rev, vpu, and env genes on a simian immunodeficiency virus (SIV) strain mac239 background readily infected several susceptible macaques. Inoculation of macaque monkeys with SHIV is an important tool for studying the early stage of an HIV-1-like infection, for elucidating the etiology of AIDS, and for evaluating the protective effects of vaccine candidates in vivo. We previously reported the in vivo properties of one of the SHIVs, SHIV-NM3rN (Kuwata et al., 1995) . To assess the role of cytokines in the pathogenesis of HIV-1-related virus infection, the SHIV-nef vector having unique restriction enzyme sites (designated as SHIV-NI) was constructed from SHIV-NM3rN. Gene-deleted SHIVs can serve as vectors that express cytokine genes in infected macaque monkeys (Enose et al., 2004; Kozyrev et al., 2002) . SHIV vectors containing a cytokine gene appear to be appropriate tools for observing the role of local production of a cytokine on virus replication, pathogenesis, and immunogenicity, especially because the inserted cytokine gene is expressed in the region where the SHIV vector replicates.
To study the role of TNF-a against HIV-1-related virus infection in an SHIV-macaque model, we constructed an SHIV in which the nef gene is replaced with a human TNF-a coding sequence (SHIV-TNF). In a previous in vitro study (Haga et al., 2002) , we showed that SHIV-TNF (i) expressed a significant amount of biologically active TNF-a, (ii) replicated better than the parental SHIV-NI in monkey peripheral blood mononuclear cells (PBMCs), and (iii) induced a more severe cell death in monkey PBMCs than did the parental SHIV-NI.
In this study, we demonstrate that inoculation of SHIV-TNF in macaque monkeys induced cell death in peripheral lymph nodes without a depletion of circulating CD4 + T cells. After the acute viremic stage, the plasma viral load declined earlier in the SHIV-TNF-inoculated monkeys than in the parental SHIV-NIinoculated monkeys. SHIV-TNF was found to produce some immunity in macaque monkeys, leading to the elimination of SHIV. Based on these results, we propose that TNF-a contributes to the induction of an effective immune response rather than to the progression of disease at the early stage of HIV-1 infection.
Results

Virus load in rhesus macaques with SHIV-NI and SHIV-TNF
A recombinant SHIV was engineered to express TNF-a (SHIV-TNF) in place of nef in SHIV-NI (Fig. 1A) . To investigate the in vivo properties of an SHIV-TNF, three rhesus monkeys (MM343, MM350, and MM351) were intravenously inoculated with 10 5 tissue culture 50% infectious dose (TCID 50 ) of SHIV-TNF, and two animals (MM346 and MM349) were inoculated with 10 5 TCID 50 of SHIV-NI as a control. All monkeys were viremic within 2 weeks postinoculation (WPI) (Fig. 2A) . This was also the case for two monkeys (MM287 and MM288) that were inoculated with same dose of SHIV-NI in a previous report (Enose et al., 2004) . The plasma viral RNA loads were about the same in all SHIV-TNF-and SHIV-NI-inoculated monkeys, reaching a peak value of 10 4 RNA copies/ml during 1 to 2 WPI. Up-regulation of the plasma viral load in the SHIV-TNF-inoculated monkeys was not more than that in the SHIV-NI-inoculated monkeys.
However, the kinetics of the viral loads was different between the two groups. At the post-acute phase, the plasma viral loads declined earlier in the SHIV-TNF group (becoming undetectable at about 4 WPI) than in the SHIV-NI group (becoming undetectable at 6 -8 WPI). After the acute viremic stage, the plasma virus load declined to undetectable levels earlier in the SHIV-TNF group than in the SHIV-NI group (P < 0.05 at 3 WPI).
Proviral DNAs in PBMCs from macaques infected with SHIV-TNF were isolated, and the stability of the inserted TNFa gene in SHIV-TNF was studied by PCR with primer pairs that recognized the site where the TNF-a gene had been inserted. Due to the limited viral replication, proviral DNAs in PBMCs of the SHIV-TNF inoculated monkeys were detected up to 3 or 4 WPI. The full-length of the inserted TNF-a was observed in the proviral DNAs (Fig. 2B ).
Lymphocyte phenotyping of PBMC and lymph nodes
After the infection, the number of peripheral CD4 + lymphocytes remained within the normal level in both the SHIV-NI-and SHIV-TNF-inoculated monkeys (Fig. 3A) . No clinical changes were observed in any of the monkeys during the observation period. These results showed that SHIV-TNF did not cause an AIDS-like disease. No significant differences were observed between the SHIV-NI-and SHIV-TNF-inoculated monkeys in the cell surface markers of PBMCs. In contrast, the percentage of CD20 + B cells in the lymph nodes changed dramatically in the SHIV-TNF-inoculated macaques after the inoculation of virus (Fig.  3B) . After the inoculation of SHIV-TNF, development of germinal centers in the lymph nodes was observed with hematoxylin and eosin staining (data not shown). These data suggest that the inoculation of SHIV-TNF induced the activation of CD20 + B cells in the lymph nodes at the early stage of the infection, without disturbing the immunological status.
Plasma levels of TNF-a and RANTES
We next examined the plasma levels of some cytokines by enzyme-linked immunosorbent assay (ELISA). The levels of TNF-a in the plasma of macaques infected with SHIV-TNF and SHIV-NI were below the detection limit (15.6 pg/ml) of the ELISA at all time points (data not shown).
TNF-a inhibited HIV-1 replication by inducing the production of CC-chemokines such as regulated-on-activation-normal-T-cell-expressed-and-secreted (RANTES) (Lane et al., 1999) . To determine whether SHIV-TNF induces the expression of RANTES, plasma levels of RANTES were investigated (Fig. 3C) . Interestingly, the plasma RANTES levels in the SHIV-TNF-infected monkeys were higher (about 3 times higher) than those in SHIV-NI-infected monkeys at 2 WPI, when the plasma viral load was about the same in the two groups. Plasma RANTES levels in the parental SHIV-NM3rN-inoculated monkeys and two other SHIV-NI-inoculated monkeys (2.7 ng/ ml for MM287 and 2.0 ng/ml for MM288, respectively, at 2 WPI) from our previous study were similar to those in the SHIV-NI-infected monkeys. The difference of the plasma RANTES levels between the SHIV-TNF-infected monkeys and the SHIV-NI-infected monkeys is statistically significant (P < 0.05 at 2 WPI). After 8 WPI, the plasma level of RANTES declined to the pre-infection level in all SHIV-TNF-infected monkeys.
Antibody titer
The humoral immune response was assessed with an HIV-1 particle agglutination assay. Induction of anti-HIV-1 antibodies was first detected in two of three SHIV-TNF-infected monkeys (MM343 and MM350) at 3 WPI (Fig. 3D ). The antibody titers for the other SHIV-TNF-inoculated monkey (MM351), SHIV-NI-inoculated monkey, and the two SHIV-NI-infected monkeys in our previous experiment (MM287 and MM288) (data not shown) all slightly increased at 4 WPI. Although the data were not statistically significant (P = 0.08 at 3 WPI), the results showed that some SHIV-TNF-infected monkeys immediately developed an antiviral antibody response during the early stage of infection.
Induction of cell death in lymph nodes of SHIV-TNF-inoculated monkeys
TNF-a induces apoptosis of lymphocytes (Zheng et al., 1995) . Spontaneous-or activation-induced ex vivo apoptosis of lymphocytes was reported in infections of HIV-1-related viruses (Gougeon et al., 1996; Iida et al., 2000; Reinberger et al., 1999) . Thus, we investigated the induction of cell death in biopsy samples from lymph nodes by Annexin V assay and terminal deoxynucleotidyl transferase dUTP nick end-labeling (TUNEL) assay. In two of the SHIV-TNF-inoculated monkeys (MM343 and MM351), the percentages of lymphocytes undergoing cell death increased 24.2% and 17.5%, respectively, at 2 WPI (Fig. 4A ). In the SHIV-NI-inoculated monkeys (Enose et al., 2004) . Plasma viral RNA loads were measured by RT-PCR. The detection limit of this assay was 1.2 Â 10 2 copies/ ml. (B) Stability of the inserted TNF-a gene in SHIV-TNF, as shown by PCR. DNA plasmids of SHIV-TNF (pSHIV-TNF DNA) and SHIV-NI (pSHIV-NI DNA) were used as the templates of the control. MWM, molecular weight markers of 100-bp ladder.
(MM346 and MM349), the percentages of Annexin-V-positive lymphocytes after the virus inoculation remained at 4.1% and 7.5%, respectively, which were the pre-inoculation levels. The percentage of Annexin-V-positive cells in the lymph nodes was markedly higher in the SHIV-TNF-inoculated macaques than in the SHIV-NI-inoculated macaques. Induction of cell death in the SHIV-TNF group was also observed by the TUNEL assay (Fig. 4B ). These results show that induction of cell death in inguinal lymph nodes in the SHIV-TNF group was significantly higher than that in SHIV-NI group, suggesting that TNF-a expressed by the SHIV-TNF-infected cells induced apoptosis in lymph nodes in the virus-inoculated monkeys.
Induction of antigen-specific lymphocyte proliferative responses in SHIV-TNF-inoculated macaques
To determine whether inoculation of the SHIV-TNF elicited antigen-specific lymphocytes in the animals, proliferative responses to SIV Gag were measured with PBMCs by uptake of 5-bromo-2V-deoxyuridine (BrdU). During the experimental period, antigen-specific T cell proliferation was induced especially in the SHIV-TNF-inoculated monkeys (Fig. 5A) . Proliferative responses to Gag in the SHIV-TNF group were observed as early as 2 WPI. Subsets of proliferative lymphocytes were also characterized by combination of anti-BrdU and surface marker staining. In the SHIV-TNF-inoculated monkeys, the antigen-specific proliferative response was observed both in CD4-positive and in CD8-positive cells (Fig. 5B) . These results show that antigen-specific T cell proliferation was induced markedly in the SHIV-TNF group at the early stage of infection.
The proliferative responses to a mitogen (Concanavalin A; ConA) were low or absent in the SHIV-NI-inoculated monkeys at 3 and 4 WPI, and then the response to ConA recovered to the normal level afterward (Fig. 5C ). In contrast, the SHIV-TNFinfected macaques showed a continuous response to ConA.
Challenge with a pathogenic SHIV
To evaluate the protective effects provided by SHIV-TNF, monkeys were challenged intravenously with 10 5 TCID 50 of heterologous pathogenic SHIV-C2/1 KS661 (Fig. 1B) at 8 WPI. As controls, four naive monkeys (MM298, MM299, MM338, and MM339) were infected intravenously with the same dose (10 5 TCID 50 ) of SHIV-C2/1 KS661. Circulating CD4 + lymphocytes decreased in all of the control monkeys, reaching less than 50 cells/Al in accordance with a previous report (Shinohara et al., 1999) (Fig. 6A) . The viral RNA in the plasma of the control monkeys increased to above 10 7 copies/ml at 1 WPI and remained at a high level (Fig. 6B) .
All of the monkeys in the SHIV-TNF group were more resistant to the challenge than the control monkeys. The circulating CD4 + T cell counts were maintained in all SHIV-TNF-infected monkeys (Fig. 6A) . The peak plasma virus loads in the SHIV-TNF group (10 5 and 10 6 copies/ml) were two orders of magnitude lower than those of the naive SHIV-C2/1 KS661-inoculated monkeys (Fig. 6B) . Interestingly, the plasma virus loads in two of the three SHIV-TNF-inoculated monkeys (MM343 and MM351) rapidly declined to below the detection limit at 4 weeks post-challenge (WPC). The peak plasma viral load of one of the SHIV-NI-infected monkeys (MM349; 10 7 copies/ml) was similar to that of the control monkeys. The circulating CD4 + T cell count in MM349, an SHIV-NI-infected monkey, remained within the normal range in spite of a transient but intense viremia in the plasma (Fig. 6A) . These results show that all SHIV-TNF-inoculated monkeys were partially protected from challenge, with a pathogenic SHIV having a heterologous HIV-1 Env. Moreover, some SHIV-TNF-infected monkeys may have immediately eliminated the heterologous challenge virus in the plasma.
Discussion
The aim of this study was to clarify the role of TNF-a against HIV-1-related virus infection in an SHIV-macaque model. For this purpose, we have genetically engineered an SHIV to express the TNF-a gene so that, when viral transcription occurs, TNF-a will also be produced locally.
We compared the in vivo properties of macaques infected with SHIV-TNF with those of its parental SHIV-NI. Although the number of animals examined was small, some virologic and immunologic parameters in macaques infected with SHIV-TNF and with SHIV-NI were different between the groups.
In a previous in vitro study, SHIV-TNF was found to replicate better than SHIV-NI does in macaque PBMCs (Haga et al., 2002) . In vivo, however, the plasma viral loads were about the same in the two groups during acute infection. The plasma viral loads in the SHIV-TNF-inoculated monkeys dramatically declined to undetectable levels after the acute phase of the infection, while the viral loads of the parental SHIV-NI-inoculated monkey declined gradually. The spread of the virus was suppressed in the animals infected with SHIV-TNF. Suppression of the virus may have been due to cell deaths in the lymph nodes from the SHIV-TNF-inoculated monkeys. An efficient induction of cell death, through the TNF/TNFreceptor (TNFR) pathway, could restrict virus replication by eliminating virus-infected cells (Herbein and O'Brien, 2000) . HIV-1-infected lymphocytes treated with TNF-a underwent apoptosis resulting in a decreased HIV-1 replication, suggesting that cell death helps to inhibit the spread of HIV-1 (Lazdins et al., 1997) . Insertion of the TNF-a gene in the SHIV induced a rapid cell death at the site where virus replicates, with a subsequent reduction of the spread of the virus.
A cytokine-expressing SIV was observed to lose the cytokine gene within several weeks in vivo (Gundlach et al., 1997) . In our study, the proviral DNA isolated from PBMCs of macaques inoculated with SHIV-TNF during the viremia retained full-length TNF-a inserts. Due to the limited and local nature of viral replication, we could not detect TNF-a in the plasma of animals inoculated with SHIV-TNF. However, the TNF-a gene inserted in SHIV-TNF was stable in vivo during the viremia.
In vitro studies have suggested that pretreatment of macrophages with TNF-a helps to protect them against HIV- 1. This is largely because TNF-a induces the secretion of CCchemokines such as macrophage inflammatory protein-1 alpha (MIP-1a), beta (MIP-1h), and RANTES (Herbein and Gordon, 1997; Lane et al., 1999) . In this experiment, an increase in RANTES production was observed in the SHIV-TNF-inoculated monkeys. At the peak, the plasma level of RANTES was three times higher in the SHIV-TNF-infected monkeys than in the SHIV-NI-infected monkeys. RANTES is known to suppress a CC-chemokine receptor 5 (R5)-tropic HIV-1 in vitro (Alkhatib et al., 1996; Cocchi et al., 1995), but not a CXCR4 (X4)-tropic virus including HIV-1 NL432, the source of the env gene of SHIV-TNF. Therefore, the high RANTES production probably did not limit the replication of SHIV-TNF in this study. Many cohort studies have suggested that an increase of RANTES inhibits the development of AIDS (Aukrust et al., 1998; Garzino-Demo et al., 1999) . Furthermore, RANTES regulates cell migration to the site of inflammation. The appropriate expression of RANTES can improve the host immune response against HIV-1. Together, our result suggests that TNF-a helps to induce an effective immune response against HIV-1 by mediating the expression of the CC-chemokine RANTES. Another finding of the present study is that the inoculation of SHIV-TNF induced a remarkable antigen-specific T cell proliferation at the early stage of infection. In human, TNF-a enhances mitogen-and antigen-induced T cell proliferation (Tartaglia et al., 1993; Yokota et al., 1988) . TNF-a produced by HIV-1-infected macrophages has been reported to stimulate bystander T cell proliferation (Godard and Chermann, 1998) . Our results suggest that the co-expression of viral antigen and TNF-a stimulates antigen-specific T cell proliferation. Antigen-specific T cell proliferation is important for the control of AIDS pathogenesis. Proliferation of HIV-1 p24-specific CD4 + T cells, which has been associated with control of acute infection and delayed disease progression, has been shown to inhibit the replication of HIV-1 (Rosenberg et al., 1997) . Therefore, TNF-a appears to induce effective antigen-specific immune responses of lymphocytes, which may help to prevent the progression of disease.
The proliferative responses to a mitogen (ConA) were low or absent in parental SHIV-NI-inoculated monkeys during the period from 3 WPI to 4 WPI. Mitogen-stimulated proliferation of lymphocytes was also found to be inhibited during the acute stage of HIV-1 infection (Cooper et al., 1988; Pedersen et al., 1990) . A transient impairment of proliferative response to mitogens has been correlated with host immune suppression. A decrease in the level of TNF-a in a virus infection was found to suppress mitogen-and antigen-stimulated lymphocyte proliferation (Griffin et al., 1994) , and mitogen-and antigenstimulated lymphocyte proliferation was restored by addition of exogenous TNF-a (Kasahara et al., 2003) . In the present study, the SHIV-TNF-infected macaques showed a continuous proliferative response to ConA during the observation period. These results suggest that co-expression of TNF-a by a genetically engineered virus sustains the virus-induced immune suppression.
Most studies of the relationship between TNF-a and HIV-1 infection have focused on patients at the AIDS stage. TNF-a has been implicated in the progression of AIDS because of the possibilities that TNF-a enhances HIV-1 replication (Folks et al., 1989; Poli et al., 1990) and induces apoptosis of lymphocytes (Badley et al., 1997; Herbein et al., 1998) . In this study, SHIV-TNF replicated transiently in inoculated monkeys, and the number of peripheral CD4 + lymphocytes remained within the normal level in all SHIV-TNF-inoculated monkeys, despite the induction of cell death in inguinal lymph nodes. Although we cannot exclude the possibility that TNF-a contributes to disease progression in the late stage of infections, the SHIV-TNF-inoculated macaques did not develop AIDS-like disease during the experimental period.
At the early stage of HIV-1 infection, expression of TNF-a also increased in some individuals (von Sydow et al., 1991) , which was considered to contribute to the inflammatory response seen in acute HIV-1 infection. The present results demonstrate that SHIV-TNF induced the expression of RANTES, antigen-specific T cell proliferation, and rapid cell death with a subsequent reduction of plasma viral loads at the early stage of infection. The appearance of TNF-a activates the virus-specific immune response, which contributes to viral clearance. Therefore, at the early stage of HIV-1 infection, we propose that TNF-a plays a role in the induction of an effective immune response, rather than in the progression of the disease.
The immune responses induced by an attenuated virus can increase the immunity to a pathogenic virus. We previously reported that macaque monkeys immunized with the parental SHIV-NI were partially protected from a challenge with a heterologous pathogenic SHIV (Enose et al., 2002; Ui et al., 1999) . In the present study, the monkeys that received the inoculation of SHIV-TNF were partially protected from a challenge with a heterologous pathogenic SHIV-C2/1. The immune response induced by the inoculation of SHIV-TNF helped to suppress the spread of a heterologous pathogenic SHIV. It is noteworthy that the challenge virus load rapidly declined to below the detection limit in some SHIV-TNFinoculated monkeys.
In general, the immunogenicity of live-attenuated vaccines tends to increase with increasing virulence (Johnson and Desrosiers, 1998) . Therefore, in attenuating a live virus, there is a trade-off between safety and immunogenicity. A good way to overcome this problem is to genetically engineer a virus to co-express an anti-viral agent such as a cytokine adjuvant. The expression of an inserted cytokine gene from a genetically engineered vaccine virus provides adjuvant effects locally at the site of virus replication. Several studies have demonstrated that insertion of a cytokine in a gene-deleted live-attenuated SIVs could boost the immunogenicity of the viruses and enhance its protection ability (Giavedoni et al., 1997; Stahl-Hennig et al., 2003) . For the immune adjuvant effect of TNF-a, a combination of cytokines including TNF-a enhanced cellular immune responses resulting in a more effective immune-modulating effect against HIV-1 in the rodent model (Ahlers et al., 1997 (Ahlers et al., , 2003 . In this study, SHIV-TNF induced antiviral immune responses in the virus-inoculated monkeys that subsequently rapidly cleared the virus. The rapid viral clearance and enhanced immunogenicity may improve the safety of a liveattenuated virus vaccine candidate because these responses will reduce the risks of residual pathogenicity, reversion to a pathogenic virus, and recombination of the vaccine virus with the challenge virus (Baba et al., 1999; Gundlach et al., 2000) . These results raise the possibility that a genetically engineered anti-viral agent, such as TNF-a, can improve the safety and immunogenicity of an attenuated live virus vaccine.
In conclusion, we showed that SHIV-TNF induces (i) rapid clearance of virus after the acute viremic stage, (ii) cell death in peripheral lymph nodes without depletion of circulating CD4 + T cells, (iii) up-regulation of the plasma level of the chemokine RANTES, (iv) antigen-specific proliferation of lymphocytes, and (v) protection against a pathogenic SHIV-C2/1 challenge. These findings suggest that TNF-a contributes to the induction of an effective immune response at the early stage of HIV-1 infection and that a genetically engineered virus to co-express the TNF-a gene can be useful for studying the immunemodulating effect of TNF-a in HIV-1-related infections.
Materials and methods
Viruses and animals
SHIV-NI and SHIV-TNF were constructed from SHIVNM3rN as previously described (Fig. 1A) (Haga et al., 2002) . A heterologous pathogenic SHIV-C2/1 KS661 was used for the challenge virus (Fig. 1B) . SHIV-C2/1 KS661 is a molecular clone derived from SHIV-C2/1 and causes rapid CD4 + T cell depletion (GenBank accession number AF217181) (Shinohara et al., 1999) . The env gene of SHIV-C2/1 was derived from HIV-1 89.6 and is antigenically different from the env gene of SHIV-NI and SHIV-TNF. Virus stocks were prepared with the CD4 + human T cell line M8166 (a subclone of C8166) as described elsewhere (Haga et al., 2002) . Five female rhesus monkeys (Macaca mulatta) were maintained in accordance with regulations approved by the Institutional Animal Care and Use Committee of the Institute for Virus Research, Kyoto University, and were housed in single cages within a biosafety level 3 facility. Blood samples were collected under anesthesia with ketamine hydrochloride.
Inoculation of rhesus monkeys with SHIV and sample collection
To investigate the in vivo properties of SHIV-TNF and SHIV-NI, three rhesus monkeys (MM343, MM350, and MM351) were inoculated intravenously with 10 5 TCID 50 of SHIV-TNF, and two monkeys (MM346 and MM349) were inoculated with 10 5 TCID 50 of SHIV-NI. Blood samples were phenotypically characterized on a FACScan flow cytometer (Becton Dickinson, San Jose, CA) and were separated into plasma and PBMCs with lymphocyte separation solution (Nacalai Tesque, Inc. Kyoto, Japan). Inguinal lymph nodes were obtained from these animals by biopsy at 2 and 4 WPI and before infection. Single-cell suspensions were prepared from the inguinal lymph nodes with a 100 Am nylon cell strainer (Becton Dickinson). Part of the inguinal lymph nodes was fixed in 4% paraformaldehyde and embedded in paraffin for histopathologic analysis. To evaluate the protective effects provided by the SHIV-TNF or SHIV-NI inoculation, all monkeys were challenged intravenously with 10 5 TCID 50 of SHIV-C2/1 KS661 at 8 WPI.
Plasma viral RNA loads
Plasma viral RNA loads were determined by quantitative RT-PCR (Enose et al., 2002; Suryanarayana et al., 1998) . The plasma viral loads of SHIV-NI, SHIV-TNF, and the challenge virus were differentially evaluated with primer pairs specific to SHIV-NM3rN and SHIV-C2/1, respectively (Enose et al., 2004) . These reactions were performed with a Prism 7700 Sequence Detector (Applied Biosystems, Foster City, CA) and analyzed using the manufacturer's software. The viral RNA in the plasma samples was quantified based on the copy number of the standard samples.
Isolation of proviral DNA
Proviral DNA was extracted from 1 Â 10 6 PBMCs and amplified by PCR with primers specific for the nef region. Cellular DNAs were extracted from PBMCs of the inoculated monkeys using DNeasy tissue kits (QIAGEN, Hilden, Germany) according to the manufacturer's recommendations. The proviral DNA fragments covering the inserted TNF-a gene in SHIV-TNF were amplified from each cellular DNA by PCR as previously described . The lengths of DNA fragments generated by this reaction were 847 bp for the SHIV containing the intact TNF-a gene and 154 bp for SHIV-NI.
Determination of TNF-a and RANTES
Plasma samples were thawed and centrifuged at 10,000 Â g for 10 min at 4 -C. TNF-a levels in the plasma were determined by ELISA using a Quantikine Human TNF-a ELISA kit (R&D Systems, Inc., Minneapolis, MN) and a Monkey TNF-a ELISA kit (Biosource International, Inc., Camarillo, CA). Plasma RANTES concentration was measured using a human RANTES ELISA kit (R&D Systems), which is known to cross-react with rhesus RANTES .
Lymphocyte analysis
Blood samples and inguinal lymph node suspensions were stained with combinations of the following monoclonal antibodies (MAbs): anti-human CD4 (NU-TH/I, Nichirei, Tokyo, Japan), anti-human CD8 (Leu-2a, Becton Dickinson), anti-monkey CD3 (FN18, Biosource International), anti-human CD20 (Leu-16, Becton Dickinson), anti-human CD29 (4B4; Beckman Coulter, Miami, FL), anti-human CD14 (RMO52; Beckman Coulter), anti-human CCR5 (3A9; Pharmingen, San Diego, CA), anti-human CXCR4 (12G5; Pharmingen), and anti-Ki67 antigen (Ki-67, DAKO, Glostrup, Denmark). Ten thousand events per sample were acquired by a FACScan flow cytometer, and data were analyzed by CellQuest software (Becton Dickinson) and FlowJo software (TreeStar, San Carlos, CA). Absolute lymphocyte counts in the blood were determined with an automated blood cell counter (F-820; Sysmex, Kobe, Japan).
Analysis of cell death
The percentages of lymphocytes undergoing cell death were determined by Annexin V assay and TUNEL assay.
Mononuclear cells (1 Â 10 6 ) from the blood and lymph nodes were cultured for 24 h ex vivo in 24-well culture plates in complete RPMI medium (RPMI 1640 with 10% heat-inactivated fetal calf serum) per milliliter at 37 -C. In the Annexin V assay, a MEBCYTO apoptosis kit (MBL, Nagoya, Japan) was used according to the manufacturer's instructions. As another assay of cell death, fragmentation of chromosomal DNA was detected with a TUNEL assay. An APO-BrdU kit (Pharmingen) was used according to the manufacturer's instructions. The cells were then analyzed by flow cytometry.
Proliferation assays
Lymphocyte proliferation was measured by incorporation of BrdU into the stimulated lymphocytes. PBMCs (2 Â 10 5 ) were cultured in a 96-well plate in complete RPMI medium. The recombinant viral proteins of SIV Gag (SIVmac251 p27; 5.0 Ag/ml; Advanced Biotechnologies, Inc., Columbia, MD) were used for antigen-specific stimulation. Concanavalin A (ConA; 0.5 Ag/ml; Sigma, St. Louis, MO) was used for polyclonal stimulation. The plates were incubated for 72 h at 37 -C. After the incubation, the cells were cultured for another 24 h in the presence of BrdU. Then, lymphocyte proliferation was measured using a cell proliferation ELISA kit (Roche Diagnostics, Basel, Switzerland) and a BrdU-Flow kit (Pharmingen) following the manufacturer's recommendations. In the ELISA, the absorbance of the incorporated BrdU was measured by a microplate reader at 450 nm. The experiment was performed in triplicate. In another cell proliferation assay, to characterize the lymphocyte subsets in the proliferated cells, cells were stained for surface markers with MAb CD4-PE (Nichirei) and CD8-PerCP (Becton Dickinson). The cells were stained with MAb BrdU-FITC after fixation and permeabilization and then analyzed by flow cytometry. Proliferation responses to the antigens were considered positive if the stimulation index (SI = titers for antigenstimulated wells / titers for control wells without antigens) exceeded 2.0 (Ahmed et al., 2002) .
Determination of anti-SHIV antibody titers
Anti-SHIV antibody titers in the plasma of the monkeys were determined using a commercial particle agglutination test kit (Genedia HIV-1/2, Fujirebio Inc., Tokyo, Japan). The samples were serially two-fold diluted and assayed following the manufacturer's recommendations. The end-point titer was determined as the highest dilution to give a positive result.
Statistical analysis
Differences between the groups of plasma viral RNA loads, plasma RANTES level, and anti-SHIV antibody titers in the plasma were compared by statistical analysis using the MannWhitney U test; P values <0.05 were considered statistically significant.
